Emerging Targets in Gastrointestinal (Gastric & Gastroesophageal) Cancers – Clinical Brief #1




Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from Astellas.


Patients with gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinomas may only represent a small percentage of your practice, but as these are aggressive cancers that confer a high mortality rate, having a working knowledge of best practices in testing and treatment selection are critical to optimal outcomes.

Advances in cancer biology and sequencing technology have enabled the selection of targeted and more effective treatments for individual patients across solid tumors. To date, three molecular biomarkers have been demonstrated to predict a response to targeted therapies in patients with gastric and/or gastroesophageal junction (G/GEJ) cancers: HER2 positivity for trastuzumab and trastuzumab deruxtecan, and microsatellite instability (MSI) status and PD-L1 expression for pembrolizumab. There are several new targets that have agents in late-stage trials: claudin 18.2-positive (CLDN18.2+) and FGFR2b.

This activity will provide details on the current best practices and what we should be anticipating in the near term.


Michael Pishvaian, MD, PhD
Associate Professor
Department of Medical Oncology
Johns Hopkins University
Washington, District of Columbia


Aatur D. Singhi, MD, PhD
Associate Professor
Department of Pathology
University of Pittsburgh Medical Center
Pittsburg, Pennsylvania


Nataliya Uboha, MD, PhD
Associate Professor
Department of Internal Medicine
Section of Hematology and Oncology
University of Wisconsin,
Carbone Cancer Center
Madison, Wisconsin


Release date: June 8, 2022
Expiration date: September 8, 2022
Estimated time to complete activity: 30 minutes



This educational activity has been designed to meet the needs of medical oncologists, gastroenterologists, pathologists and other HCPs who treat or manage patients with gastric and/or gastroesophageal cancers.


Upon completion of this educational activity, participants should be able to:

  • Select optimal testing methods and timing for patients diagnosed with gastric, gastroesophageal, and gastroesophageal junction cancer
  • Select patients and incorporate liquid biopsy into clinical practice
  • Assess testing methods and interpretation for currently approved molecular biomarkers

There are no fees for participating and receiving CME credit for this activity. During the period of June 8, 2022 through September 8, 2022, participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Michael Pishvaian MD, PhD
Advisor:  AstraZeneca, Merck, Novartis, Pfizer
Funding: Amgen, Arcus Bio, Astra Zeneca, Biomedical Valley, Daichi Sankyo, Ideaya, Merck, Pfizer, Repare RX, Seattle Genetics, Tizonia
Stock: Perthera

Aatur D. Singhi, MD, PhD
Consultant: Foundation Medicine

Nataliya V. Uboha
Advisor: Astellas, AstraZeneca, Boston Gene, Helsinn, Incyte, QED, Taiho
Research Support: Ipsen, Taiho

 The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest